Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up.

Ken Kato,Yuichiro Doki,Takashi Ura,Yasuo Hamamoto,Takashi Kojima,Takahiro Tsushima,Shuichi Hironaka,Hiroki Hara,Taroh Satoh,Satoru Iwasa,Kei Muro,Hirofumi Yasui,Keiko Minashi,Kensei Yamaguchi,Atsushi Ohtsu,Yuko Kitagawa

Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO-4538-07): Minimum of five-year follow-up.

2021

Ken Kato
Yuichiro Doki
Takashi Ura
Yasuo Hamamoto
Takashi Kojima
Takahiro Tsushima
Shuichi Hironaka
Hiroki Hara
Taroh Satoh
Satoru Iwasa
Kei Muro
Hirofumi Yasui
Keiko Minashi
Kensei Yamaguchi
Atsushi Ohtsu
Yuko Kitagawa

207Background:ATTRACTION-1/ONO-4538-07 (AT-1), an open-label, single-arm, multicenter phase 2 clinical trial conducted in Japan, evaluated the clinical activity and safety of nivolumab in patients ...

Keywords:

Internal medicine
esophageal squamous cell carcinoma
Oncology
in patient
Nivolumab
five year follow up
Phases of clinical research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations